Rare Disease Gene Therapy Stocks Surge 7% Amid Adversity: Are Investors Returning?

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) closed the most recent trading day at $29.50, up 7.51%. Volume totaled about 1.53 million shares, and market capitalization rose by roughly $236 million to approximately $2.9 billion (about ₩3.9 trillion).

In its first quarter, the company reported a net loss of approximately $185 million (around ₩250 billion), exceeding market expectations. Insider selling continued, with board member Corazón Sanders disposing of 2,000 common shares for about $50,100. In April, the U.S. Food and Drug Administration accepted for review Ultragenyx’s re-submitted biologics license application for UX111, its gene therapy for Sanfilippo syndrome type A, setting a PDUFA date in late August—an upcoming regulatory catalyst.

Headquartered in Novato, California, Ultragenyx specializes in treatments for rare and ultra-rare genetic diseases. It already markets therapies such as Crysvita and maintains a robust late-stage clinical pipeline. Meanwhile, a securities class action and related investigations over clinical data and disclosures for setrusumab, an investigational treatment for osteogenesis imperfecta, are ongoing—potential regulatory and legal risks that may heighten the stock’s volatility.